Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15923160rdf:typepubmed:Citationlld:pubmed
pubmed-article:15923160lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:15923160lifeskim:mentionsumls-concept:C0370003lld:lifeskim
pubmed-article:15923160lifeskim:mentionsumls-concept:C0034754lld:lifeskim
pubmed-article:15923160lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:15923160lifeskim:mentionsumls-concept:C0162789lld:lifeskim
pubmed-article:15923160lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:15923160lifeskim:mentionsumls-concept:C1521871lld:lifeskim
pubmed-article:15923160pubmed:issue1lld:pubmed
pubmed-article:15923160pubmed:dateCreated2005-5-30lld:pubmed
pubmed-article:15923160pubmed:abstractTextWe conducted this study to ascertain the prevalence of erb-b2 gene amplification in breast cancer specimens read as 2+ in immunohistochemical analysis. Slides from patients with metastatic or recurrent breast cancer were eligible for fluorescent in situ hybridization (FISH) study if they were read as 2+ immunohistochemically for erb-b2 by a certified pathologist. The PathVysion kit (Vysis, Downers Grove, IL) was used for FISH studies. Amplification of the erb-b2 gene was defined as an erb-b2/CEP17 (chromosome 17 centromere) ratio of 2 or more in 30 tumor cells counted. From May 2003 to June 2004, 221 slides were submitted from 24 hospitals around the island. Of 216 successful hybridizations, 96 (44.4%) were determined to be erb-b2 amplified. In addition, the topoisomerase IIa gene was coamplified in 11 (21%) of 53 and deleted in 8 (15%) of 53 erb-b2 amplified cases. The erb-b2 gene amplification rate was very high in cases determined to be 2+ by immunohistochemical analysis; therefore, determination of erb-b2 status by FISH in cases scored 2+ immunohistochemically is strongly recommended.lld:pubmed
pubmed-article:15923160pubmed:languageenglld:pubmed
pubmed-article:15923160pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15923160pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15923160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15923160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15923160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15923160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15923160pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15923160pubmed:statusMEDLINElld:pubmed
pubmed-article:15923160pubmed:monthJullld:pubmed
pubmed-article:15923160pubmed:issn0002-9173lld:pubmed
pubmed-article:15923160pubmed:authorpubmed-author:LiuTsang-WuTWlld:pubmed
pubmed-article:15923160pubmed:authorpubmed-author:LiuJacqueline...lld:pubmed
pubmed-article:15923160pubmed:authorpubmed-author:LanChiehClld:pubmed
pubmed-article:15923160pubmed:authorpubmed-author:ChenJim-RayJRlld:pubmed
pubmed-article:15923160pubmed:authorpubmed-author:PengJacquelin...lld:pubmed
pubmed-article:15923160pubmed:authorpubmed-author:HsuDer-HungDHlld:pubmed
pubmed-article:15923160pubmed:authorpubmed-author:LiangSuchingSlld:pubmed
pubmed-article:15923160pubmed:issnTypePrintlld:pubmed
pubmed-article:15923160pubmed:volume124lld:pubmed
pubmed-article:15923160pubmed:ownerNLMlld:pubmed
pubmed-article:15923160pubmed:authorsCompleteYlld:pubmed
pubmed-article:15923160pubmed:pagination97-102lld:pubmed
pubmed-article:15923160pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:meshHeadingpubmed-meshheading:15923160...lld:pubmed
pubmed-article:15923160pubmed:year2005lld:pubmed
pubmed-article:15923160pubmed:articleTitleerb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis.lld:pubmed
pubmed-article:15923160pubmed:affiliationDivision of Cancer Research, National Health Research Institutes, Taipei, Taiwan.lld:pubmed
pubmed-article:15923160pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15923160pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15923160pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15923160lld:pubmed